Societe Generale’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Societe Generale’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$117K	Buy	+7,078	New	+$115K	﹤0.01%	2325

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Societe Generale's HZNP Position: Q2 2016 in Review

Societe Generale opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2016: 7,078 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #2325 among its holdings.

198 funds tracked by Wall St. Rank hold HZNP as of Q2 2016.

Societe Generale held 7,078 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $117K as of Q2 2016.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new Societe Generale position in Q2 2016.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2325 holding.
198 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.